Radiomics-based prediction of local control in patients with brain metastases following postoperative stereotactic radiotherapy

Author:

Buchner Josef A.,Kofler Florian,Mayinger Michael,Christ Sebastian M.,Brunner Thomas B.,Wittig Andrea,Menze Bjoern,Zimmer Claus,Meyer Bernhard,Guckenberger Matthias,Andratschke Nicolaus,El Shafie Rami A.,Debus Jürgen,Rogers Susanne,Riesterer Oliver,Schulze Katrin,Feldmann Horst J.,Blanck Oliver,Zamboglou Constantinos,Ferentinos Konstantinos,Bilger-Zähringer Angelika,Grosu Anca L.,Wolff Robert,Piraud Marie,Eitz Kerstin A.,Combs Stephanie E.,Bernhardt Denise,Rueckert Daniel,Wiestler Benedikt,Peeken Jan C.

Abstract

AbstractBackgroundSurgical resection is the standard of care for patients with large or symptomatic brain metastases (BMs). Despite improved local control after adjuvant stereotactic radiotherapy, the local failure (LF) risk persists. Therefore, we aimed to develop and externally validate a pre-therapeutic radiomics-based prediction tool to identify patients at high LF risk.MethodsData were collected fromA Multicenter Analysis of Stereotactic Radiotherapy to the Resection Cavity of Brain Metastases(AURORA) retrospective study (training cohort: 253 patients (two centers); external test cohort: 99 patients (five centers)). Radiomic features were extracted from the contrast-enhancing BM (T1-CE MRI sequence) and the surrounding edema (FLAIR sequence). Different combinations of radiomic and clinical features were compared. The final models were trained on the entire training cohort with the best parameters previously determined by internal 5-fold cross-validation and tested on the external test set.ResultsThe best performance in the external test was achieved by an elastic net regression model trained with a combination of radiomic and clinical features with a concordance index (CI) of 0.77, outperforming any clinical model (best CI: 0.70). The model effectively stratified patients by LF risk in a Kaplan-Meier analysis (p < 0.001) and demonstrated an incremental net clinical benefit. At 24 months, we found LF in 9% and 74% of the low and high-risk groups, respectively.ConclusionsA combination of clinical and radiomic features predicted freedom from LF better than any clinical feature set alone. Patients at high risk for LF may benefit from stricter follow-up routines or intensified therapy.Key pointsRadiomics can predict the freedom from local failure in brain metastasis patientsClinical and MRI-based radiomic features combined performed better than either aloneThe proposed model significantly stratifies patients according to their riskImportance of the StudyLocal failure after treatment of brain metastases has a severe impact on patients, often resulting in additional therapy and loss of quality of life. This multicenter study investigated the possibility of predicting local failure of brain metastases after surgical resection and stereotactic radiotherapy using radiomic features extracted from the contrast-enhancing metastases and the surrounding FLAIR-hyperintense edema.By interpreting this as a survival task rather than a classification task, we were able to predict the freedom from failure probability at different time points and appropriately account for the censoring present in clinical time-to-event data.We found that synergistically combining clinical and imaging data performed better than either alone in the multicenter external test cohort, highlighting the potential of multimodal data analysis in this challenging task. Our results could improve the management of patients with brain metastases by tailoring follow-up and therapy to their individual risk of local failure.

Publisher

Cold Spring Harbor Laboratory

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3